X

Trial Profile

A Phase 1 study to evaluate the pharmacokinetics (PK) and safety of HY-004 oral solution

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tranexamic acid (Primary)
Indications Haemorrhage
Focus Adverse reactions; Pharmacokinetics
Sponsors Hyloris Pharmaceuticals

Most Recent Events

14 Feb 2024 According to a Hyloris Pharmaceuticals media release, data from this Phase 1 allowed Hyloris to define the optimal administration regimen for its proprietary oral solution for the current Phase 3 trial.
20 Jul 2022 Results published in Hyloris Pharmaceuticals Media Release.
16 Mar 2022 According to a Hyloris Pharmaceuticals media release, results expected in Q2 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com